Preclinical Product Articles & Analysis: Older
18 news found
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. ...
Vaccine development involves a variety of assays to support vaccine research and development, from early preclinical studies to final production, quality control and lot release. ...
Mulinacci brings a strong background in business development, strategic partnering activities involving technology platforms and clinical and preclinical stage oncology products, contract negotiation and alliance management experience to the team. ...
Formulation development is of paramount importance for new drug development as it can determine patentability, lifecycle and, ultimately, the success of a pharmaceutical product. Fully aware of the challenges that may arise from this process, CD Formulation recently announces that it now provides a comprehensive range of formulation development and analytical services for the ...
(Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. ...
About XyloCor XyloCor Therapeutics is a private, clinical-stage biopharmaceutical company developing potential best-in-class gene therapies to transform outcomes for patients with cardiovascular disease. The company’s lead product candidate, XC001, is currently being investigated in a Phase 2 clinical trial for patients with refractory angina for which there are no ...
View the full release here: https://www.businesswire.com/news/home/20220105005121/en/ “Preclinical and early clinical data have demonstrated enhanced anti-tumor activity by the combination of HIF2α and VEGFR inhibition. ...
Phase 1/2a clinical trial data on our lead product candidate, EVX-01, showed that 67% of the patients benefited from EVX-01 in combination with anti-PD-1 for the treatment of metastatic melanoma, compared to the historical data of only 40% benefiting from the check point inhibitor alone. ...
Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for LAVA’s product candidates, and the potential use of our product candidates to treat various tumor targets. Many factors may cause ...
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device industry and ear, nose and throat-specific experience to the company that will support commercial advancement of Neurent’s proprietary NEUROMARK™ ...
Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive positioning, and strengthen its business development and fundraising efforts. ...
ByAbologix
Both this study and our Phase 1/2a trial with EVX-01 remain on track and our other product candidates – EVX-03 for multiple cancer indications and EVX-B1, a vaccine for prevention of S. aureus – are progressing well through preclinical ...
Arquimea is a cross-sectoral international technology group developing solutions and innovative products in highly demanding activity sectors. With this investment on Vaxdyn, the fight against antibiotic-resistant bacteria joins other strategic areas in the healthcare division of Arquimea, like Covid-19 diagnostics, diagnostics based on epigenetic markers, and innovative ...
(Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. ...
“Deep Genomics is the first company I’ve encountered in which I see a direct connection between their AI systems and faster and more accurate production of preclinical and clinical candidates. I am excited to join this interdisciplinary ...
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X, a non-profit partnership investing $500 million in the development of innovative vaccines, ...
EFRO aims to strengthen the regional economy by supporting local businesses to improve their competitive position, economic growth, and sustainable development, as well as by increasing employment opportunities. As the first product in Polyganics’ General Surgery portfolio, the innovative Liver and Pancreas Sealant Patch is integral to the Company’s growth strategy. ...
ByRegenity
Yoder. a Vascugen founder and IU Distinguished Professor Emeritus. They broadly cover related products and services for research, diagnostics, therapeutics, tissue engineering and 3-D printing applications arising from the technology. ...